Savara (SVRA) announced the European Patent Office notified the company of its intention to grant a patent application covering the liquid formulation of Molbreevi, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
- Savara rumor highlighted in Betaville blog
- Savara issues patent for Molbreevi from European Patent Office
- Savara’s MOLBREEVI: Promising Potential in APAP Market with Strategic Expert Engagement
- Savara Inc. Reports Q3 2025 Financial Results